Strides Pharma gets USFDA’s nod for greenfield oral dosage facility in Singapore
27th Mar 2019

Strides Pharma Science (Strides) has received the United States Food & Drug Administration (USFDA) approval for its greenfield oral dosage facility in Singapore. With the commercialization of its manufacturing facility in Singapore, Strides will join the  league  of  global  pharmaceutical  companies  having a Manufacturing  and  Research  and  Development footprint in Singapore. 

The  facility  will  complement  Strides’  existing  manufacturing  base  and  will  help  meet  increased demand from its fast-growing regulated markets business across US, Australia,  UK and Europe. The facility operating at its peak capacity will produce around 1.4 billion tablets and hard gelatin capsules.  

Strides Pharma Science (Formerly Strides Shasun) is a pharmaceutical company with a major focus on development and manufacture of IP-led niche finished dosage formulations. It is also among the world’s largest manufacturers of soft gelatin capsules.